查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1722643

抗纖溶藥物市場報告（按適應症、劑型、最終用戶和地區）2025-2033

Antifibrinolytic Drugs Market Report by Indication, Form, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球抗纖溶藥物市場規模達 176 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 250 億美元，2025-2033 年期間的成長率 (CAGR) 為 3.77%。

抗纖溶藥物是指用於促進血塊形成，以防止纖維蛋白溶解或動脈、靜脈阻塞的藥物。這些藥物抑制纖溶酶原的活化，從而防止纖維蛋白的溶解並維持血塊的穩定性。它們用於治療出血、血管腫瘤和緩解月經過多。它們也用於控制侵入性手術期間或之後的出血。一些常見的抗纖維蛋白溶解藥物包括氨甲環酸、抑肽酶、氨基己酸和絲氨酸蛋白酶抑制劑。它們廣泛用於治療口咽、鼻腔、胃腸道和子宮陰道內壁的黏膜出血。因此，它們被廣泛應用於醫院、診所、創傷和門診手術中心。

抗纖溶藥物市場趨勢：

道路交通事故、創傷和各種出血性疾病發生率的上升是推動市場成長的關鍵因素之一。此外，抗纖維蛋白溶解藥物的廣泛採用，以防止月經過多以及心血管和神經外科手術期間的女性失血，也為市場成長提供了推動力。抗纖維蛋白溶解藥物對於防止血塊溶解和減少失血至關重要。同時，群眾健康意識的增強以及對遺傳性血管性水腫和血友病可用治療替代方案的認知也促進了市場的成長。各種技術進步和抗纖溶療法的日益普及以減少骨科患者輸血，是其他促進成長的因素。藥廠也正在開發具有增強功效和生物吸收性的創新口服和靜脈注射藥物。其他因素，包括老年人口的增加和醫療保健基礎設施的顯著改善，預計將推動市場成長。

本報告回答的關鍵問題

  • 抗纖溶藥物市場有多大？ 2025-2033年全球抗纖溶藥物市場的預期成長率為何？
  • 推動全球抗纖溶藥物市場發展的關鍵因素有哪些？
  • COVID-19 對全球抗纖溶藥物市場有何影響？
  • 根據適應症，全球抗纖溶藥物市場如何分佈？
  • 全球抗纖溶藥物市場的主要區域有哪些？
  • 全球抗纖溶藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球抗纖溶藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依指標

  • 婦科
  • 遺傳性血管性水腫
  • 纖溶反應檢測
  • 手術
  • 其他

第7章：市場區隔：依形式

  • 口服
  • 注射劑

第8章：市場區隔：按最終用戶

  • 醫院和診所
  • 門診手術中心
  • 創傷中心
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • ACIC Pharmaceuticals Inc.
    • Akorn Inc.
    • Aurobindo Pharma Limited
    • Ferring Pharmaceuticals
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
    • Vitruvias Therapeutics Inc.
Product Code: SR112025A5672

The global antifibrinolytic drugs market size reached USD 17.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.77% during 2025-2033.

Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.

Antifibrinolytic Drugs Market Trends:

The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Indication:

  • Gynecology
  • Hereditary Angioedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others

Breakup by Form:

  • Oral
  • Injectable

Breakup by End User:

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Trauma Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Key Questions Answered in This Report

  • 1.How big is the antifibrinolytic drugs market?
  • 2.What is the expected growth rate of the global antifibrinolytic drugs market during 2025-2033?
  • 3.What are the key factors driving the global antifibrinolytic drugs market?
  • 4.What has been the impact of COVID-19 on the global antifibrinolytic drugs market?
  • 5.What is the breakup of the global antifibrinolytic drugs market based on the indication?
  • 6.What are the key regions in the global antifibrinolytic drugs market?
  • 7.Who are the key players/companies in the global antifibrinolytic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antifibrinolytic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Gynecology
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hereditary Angioedema
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Fibrinolytic Response Testing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Surgeries
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Form

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Trauma Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ACIC Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Akorn Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Aurobindo Pharma Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Ferring Pharmaceuticals
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Takeda Pharmaceutical Company Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Viatris Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Vitruvias Therapeutics Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antifibrinolytic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antifibrinolytic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antifibrinolytic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antifibrinolytic Drugs Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Antifibrinolytic Drugs Market: Breakup by Form (in %), 2024
  • Figure 6: Global: Antifibrinolytic Drugs Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Antifibrinolytic Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antifibrinolytic Drugs (Gynecology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antifibrinolytic Drugs (Gynecology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antifibrinolytic Drugs (Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antifibrinolytic Drugs (Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antifibrinolytic Drugs (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antifibrinolytic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antifibrinolytic Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antifibrinolytic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antifibrinolytic Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antifibrinolytic Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antifibrinolytic Drugs (Trauma Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antifibrinolytic Drugs (Trauma Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antifibrinolytic Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antifibrinolytic Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Antifibrinolytic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Antifibrinolytic Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Antifibrinolytic Drugs Industry: SWOT Analysis
  • Figure 80: Global: Antifibrinolytic Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Antifibrinolytic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antifibrinolytic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Form (in Million USD), 2025-2033
  • Table 4: Global: Antifibrinolytic Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antifibrinolytic Drugs Market: Competitive Structure
  • Table 7: Global: Antifibrinolytic Drugs Market: Key Players